Roche granted FDA Breakthrough Device Designation
Roche announces that the Tina-quant lipoprotein Lp(a) RxDx assay receives Breakthrough Device Designation from the FDA
Stay updated with breaking news from Matt Sause. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Roche announces that the Tina-quant lipoprotein Lp(a) RxDx assay receives Breakthrough Device Designation from the FDA
Approximately one in five people worldwide have elevated Lp levels, putting them at increased risk of cardiovascular diseases including myocardial infarction and stroke.1The Roche Diagnostics...
Approximately one in five people worldwide have elevated Lp(a) levels, putting them at increased risk of cardiovascular diseases including myocardial infarction and stroke.1The Roche Diagnostics Tina-quant®
In 2014, the cobas human papillomavirus test was approved by the FDA for first-line, primary screening in women aged 25 years and older.
Expanding access and screening options to help eliminate cervical cancer